Last month's top 10 short squeeze candidates — how did they actually do?
On 2026-07-02, our composite squeeze score flagged the ten names below as the highest-readiness candidates on the board — high short interest, rising days-to-cover, and at least one bullish technical setup confirming the squeeze thesis.
Over the next 30 calendar days (through 2026-07-31), the basket punished anyone who simply bought and held. The average peak gain was +7.5%, against an average drawdown of -23.6% and an average buy-and-hold return of -18.2%. 2 of 10 names closed green; 7 lost more than 20%.
The screener surfaced lukewarm bounces at best — PRME alone touched +24.7% intra-window — but as is typical for short squeeze setups, the winners failed to outrun the losers when held to today. Most names rolled over before any squeeze fully developed. Below is each candidate, in order of composite score, with the price action that followed.
The numbers, top-to-bottom
| # | Ticker | Company | Score | SI % | DTC | Peak | Drawdown | Held to today |
|---|---|---|---|---|---|---|---|---|
| 1 | PSKY | Paramount Skydance Corporation Class B Common Stock | 97.7 | 25.0% | 10.6 | -0.2% | -26.7% | -23.4% |
| 2 | PRME | Prime Medicine, Inc. Common Stock | 97.2 | 46.6% | 11.3 | +24.7% | -26.1% | -24.5% |
| 3 | GPGI | GPGI, Inc. | 97.1 | 28.4% | 18.1 | +3.5% | -22.1% | -21.2% |
| 4 | HURA | TuHURA Biosciences, Inc. Common Stock | 95.7 | 32.0% | 16.6 | +6.6% | -18.2% | -11.1% |
| 5 | SION | Sionna Therapeutics, Inc. Common Stock | 94.3 | 60.4% | 13.9 | +17.2% | -5.2% | +7.1% |
| 6 | GLSI | Greenwich LifeSciences, Inc. | 94.2 | 25.0% | 9.0 | +1.3% | -43.1% | -38.6% |
| 7 | SANA | Sana Biotechnology, Inc. Common Stock | 93.9 | 25.8% | 11.1 | +5.0% | -24.4% | -21.9% |
| 8 | IBRX | ImmunityBio, Inc. Common Stock | 93.3 | 36.7% | 11.9 | +1.0% | -29.6% | -24.0% |
| 9 | IBTA | Ibotta, Inc. | 93.2 | 42.6% | 16.8 | -0.0% | -33.0% | -32.5% |
| 10 | KOD | Kodiak Sciences Inc Common Stock | 93.0 | 33.6% | 13.7 | +16.4% | -7.2% | +7.9% |
Ticker by ticker
#1. PSKY — Paramount Skydance Corporation Class B Common Stock · $11.0B · score 97.7
PSKY (Paramount Skydance Corporation Class B Common Stock) ($11.0B) Entertainment & Gaming sector — entered the window at $10.39. A critical-risk reading on the squeeze board: a composite of 97.7 backed by 25.0% of float and 10.6 days-to-cover. The squeeze never really fired — the best print was $10.37 on the 1st session, only -0.2% off the entry. The other side of the trade hurt: $7.62 on the 20th session (-26.7% from entry) was the worst of it. Net of the trip, this one is -23.4% — the worst-case outcome for a screener pick.
#2. PRME — Prime Medicine, Inc. Common Stock · $666M · score 97.2
PRME (Prime Medicine, Inc. Common Stock) ($666M) Healthcare - Genomics & Precision Medicine sector — entered the window at $3.87. A critical-risk reading on the squeeze board: a composite of 97.2 backed by 46.6% of float and 11.3 days-to-cover. The squeeze did show up — price ran to $4.83 by the 3rd session, a +24.7% move from entry. The other side of the trade hurt: $2.86 on the 15th session (-26.1% from entry) was the worst of it. Net of the trip, this one is -24.5% — the worst-case outcome for a screener pick.
#3. GPGI — GPGI, Inc. · $4.6B · score 97.1
GPGI (GPGI, Inc.) ($4.6B) Asset Management & Capital Markets sector — entered the window at $16.75. On the day, our composite tagged it critical: a composite of 97.1 backed by 28.4% of float and 18.1 days-to-cover. Squeeze risk on paper, no squeeze in the tape — high of $17.33 on the 1st session, just +3.5% above entry. Drawdown was steep — the 20th session saw price tag $13.05, a -22.1% retrace from the start. Held to today, the trade prints a brutal -21.2%. The squeeze never showed up; the sellers did.
#4. HURA — TuHURA Biosciences, Inc. Common Stock · $149M · score 95.7
HURA (TuHURA Biosciences, Inc. Common Stock) ($149M) Healthcare - Oncology sector — entered the window at $2.44. A critical-risk reading on the squeeze board: a composite of 95.7 backed by 32.0% of float and 16.6 days-to-cover. The squeeze never really fired — the best print was $2.60 on the 6th session, only +6.6% off the entry. The other side of the trade hurt: $2.00 on the 18th session (-18.2% from entry) was the worst of it. As of yesterday's close the trade sits at -11.1% — the setup looked good on paper but the market disagreed.
#5. SION — Sionna Therapeutics, Inc. Common Stock · $2.0B · score 94.3
SION (Sionna Therapeutics, Inc. Common Stock) ($2.0B) Biotech - Drug Development sector — entered the window at $43.99. On the day, our composite tagged it critical: a composite of 94.3 backed by 60.4% of float and 13.9 days-to-cover. The thesis paid off briefly — buyers pushed the tape to $51.56 on the 11th session for a +17.2% pop. Drawdown stayed manageable — only -5.2% to $41.69 on the 8th session. As of last night's close the position is +7.1% from entry, a wash after a volatile month.
#6. GLSI — Greenwich LifeSciences, Inc. · $344M · score 94.2
GLSI (Greenwich LifeSciences, Inc.) ($344M) Healthcare - Oncology sector — entered the window at $22.00. The score flagged it as critical-risk squeeze: a composite of 94.2 backed by 25.0% of float and 9.0 days-to-cover. Bulls couldn't get traction; the 1st session marked the high at $22.28 (+1.3% from entry) and that was it. Short sellers had their innings too — the 15th session bottomed at $12.51, -43.1% below the entry close. As of last night the position is down -38.6% — a textbook example of why squeeze setups need a stop.
#7. SANA — Sana Biotechnology, Inc. Common Stock · $971M · score 93.9
SANA (Sana Biotechnology, Inc. Common Stock) ($971M) Biotech - Drug Development sector — entered the window at $4.01. On the day, our composite tagged it critical: a composite of 93.9 backed by 25.8% of float and 11.1 days-to-cover. Squeeze risk on paper, no squeeze in the tape — high of $4.21 on the 3rd session, just +5.0% above entry. Drawdown was steep — the 18th session saw price tag $3.03, a -24.4% retrace from the start. Held to today, the trade prints a brutal -21.9%. The squeeze never showed up; the sellers did.
#8. IBRX — ImmunityBio, Inc. Common Stock · $9.2B · score 93.3
IBRX (ImmunityBio, Inc. Common Stock) ($9.2B) Healthcare - Oncology sector — entered the window at $9.44. The score flagged it as critical-risk squeeze: a composite of 93.3 backed by 36.7% of float and 11.9 days-to-cover. Bulls couldn't get traction; the 1st session marked the high at $9.53 (+1.0% from entry) and that was it. Short sellers had their innings too — the 17th session bottomed at $6.65, -29.6% below the entry close. As of last night the position is down -24.0% — a textbook example of why squeeze setups need a stop.
#9. IBTA — Ibotta, Inc. · $795M · score 93.2
IBTA (Ibotta, Inc.) ($795M) E-Commerce & Digital Retail sector — entered the window at $35.57. On the day, our composite tagged it critical: a composite of 93.2 backed by 42.6% of float and 16.8 days-to-cover. Squeeze risk on paper, no squeeze in the tape — high of $35.56 on the 1st session, just -0.0% above entry. Drawdown was steep — the 20th session saw price tag $23.84, a -33.0% retrace from the start. Held to today, the trade prints a brutal -32.5%. The squeeze never showed up; the sellers did.
#10. KOD — Kodiak Sciences Inc Common Stock · $2.4B · score 93.0
KOD (Kodiak Sciences Inc Common Stock) ($2.4B) Biotech - Drug Development sector — entered the window at $38.54. On the day, our composite tagged it critical: a composite of 93.0 backed by 33.6% of float and 13.7 days-to-cover. The thesis paid off briefly — buyers pushed the tape to $44.85 on the 11th session for a +16.4% pop. Drawdown stayed manageable — only -7.2% to $35.77 on the 2nd session. As of last night's close the position is +7.9% from entry, a wash after a volatile month.